Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Alexza, Teva deal

    Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Alexza will regain U.S. rights to Adasuve loxapine from Teva, …

    Published on 11/23/2015
  • Aptose Biosciences, Laxai Avanti Life Sciences deal

    Aptose Biosciences Inc. (TSX:APS;NASDAQ:APTO), Toronto, Ontario Laxai Avanti Life Sciences Pvt. Ltd., Hyderabad, India Business: Supply/Service, Cancer Aptose partnered with CRO Laxai Avanti Life Sciences to develop …

    Published on 11/23/2015
  • Array BioPharma, Pierre Fabre deal

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Laboratoires Pierre Fabre S.A., Castres, France Business: Cancer Array granted Pierre Fabre exclusive, worldwide rights, excluding the U.S., Canada, Japan, Korea and …

    Published on 11/23/2015
  • Aslan, Hyundai Pharm deal

    Aslan Pharmaceuticals Pte. Ltd., Singapore Hyundai Pharm. Co. Ltd. (KOSDAQ:A004310), Seoul, South Korea Business: Cancer Aslan granted Hyundai exclusive South Korean rights to develop and commercialize varlitinib (…

    Published on 11/23/2015
  • AstraZeneca, Sanofi deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Pharmaceuticals, High throughput screening AstraZeneca and Sanofi partnered to exchange 210,000 compounds for …

    Published on 11/23/2015
  • Cancer Research UK, Medivir deal

    Cancer Research UK, London, U.K. Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Cancer Medivir terminated an April partnership with Cancer Research UKs Cancer Research Technology (CRT) Ltd. commercialization and …

    Published on 11/23/2015
  • Cellectis, Servier deal

    Cellectis S.A. (Euronext:ALCLS;NASDAQ:CLLS), Paris, France Servier, Neuilly-sur-Seine, France Business: Cancer Servier exercised early a 2014 option from Cellectis to license worldwide rights to develop and …

    Published on 11/23/2015
  • Chugai, Kowa, Sanofi deal

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Kowa Co. Ltd., Nagoya, Japan Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Endocrine/Metabolic Kowa and Chugai expanded a 2012 deal to develop Chugais …

    Published on 11/23/2015
  • City of Hope, Tara Immuno-Oncology deal

    City of Hope, Duarte, Calif. Tara Immuno-Oncology LLC, New York, N.Y. Business: Cancer City of Hope granted Tara exclusive rights to develop and commercialize p53MVA and shIDO-ST immunotherapies to treat cancer. City of…

    Published on 11/23/2015
  • CytomX, University of Texas MD Anderson Cancer Center deal

    CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer CytomX and MD Anderson will research Probody-enabled chimeric antigen …

    Published on 11/23/2015
  • Educational and Scientific, University of Maryland deal

    Educational and Scientific LLC, Baltimore, Md. University of Maryland, College Park, Md. Business: Cancer The University of Marylands tech transfer arm granted Educational and Scientific exclusive, worldwide rights to a…

    Published on 11/23/2015
  • Eisai, Institut Paoli-Calmettes deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Institut Paoli-Calmettes, Marseille, France Business: Cancer Eisai and the non-profit partnered to develop cancer targets and therapies. IPC will perform virtual chemo-…

    Published on 11/23/2015
  • Eisai, Medicines for Malaria Venture deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Medicines for Malaria Venture, Geneva, Switzerland Business: Infectious Eisai and the non-profit partnered to develop compounds against treatment-resistant malaria parasites. …

    Published on 11/23/2015
  • Eisai, University of Liverpool, Liverpool School of Tropical Medicine deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan University of Liverpool, Liverpool, U.K. Liverpool School of Tropical Medicine, Liverpool, U.K. Business: Infectious Eisai partnered with the Liverpool School of Tropical …

    Published on 11/23/2015
  • Eli Lilly, Ignyta deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Ignyta Inc. (NASDAQ:RXDX), San Diego, Calif. Business: Cancer Eli Lilly granted Ignyta exclusive, worldwide rights to develop and commercialize oral and topical taladegib…

    Published on 11/23/2015
  • Eutropics, Tolero Pharmaceuticals deal

    Eutropics Pharmaceuticals Inc., Cambridge, Mass. Tolero Pharmaceuticals Inc., Lehi, Utah Business: Cancer Eutropics granted Tolero exclusive rights to use Eutropics Praedicare-Dx biomarker platform in the development of…

    Published on 11/23/2015
  • Evotec, Beyond Batten Disease Foundation deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Beyond Batten Disease Foundation, Austin, Texas Business: Neurology Evotec partnered with the Beyond Batten Disease Foundation to discover and develop treatments for juvenile …

    Published on 11/23/2015
  • Genexine, Tasly Pharmaceutical deal

    Genexine Co. Ltd. (KOSDAQ:095700), Seoul, South Korea Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), Tianjin, China Business: Autoimmune, Endocrine/Metabolic, Gastrointestinal Genexine granted Tasly Chinese rights to …

    Published on 11/23/2015
  • Genocea, Memorial Sloan Kettering deal

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Memorial Sloan Kettering Cancer Center, New York, N.Y. Business: Cancer Genocea partnered with the cancer center to identify T cell cancer vaccine antigens. The …

    Published on 11/23/2015
  • GUB Unternehmensbeteiligungen GmbH & Co. KGaA, VC Fonds Berlin GmbH, BioGenes deal

    GUB Unternehmensbeteiligungen GmbH & Co. KGaA, Plauen, Germany VC Fonds Berlin GmbH, Berlin, Germany BioGenes GmbH, Berlin, Germany Business: Antibodies Immunoassay and antibody developer BioGenes bought out all …

    Published on 11/23/2015
  • H. Lee Moffitt Cancer Center, Aptose Biosciences deal

    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla. Aptose Biosciences Inc. (TSX:APS;NASDAQ:APTO), Toronto, Ontario Business: Cancer Moffitt Cancer Center granted Aptose exclusive, worldwide rights to …

    Published on 11/23/2015
  • Interprotein, Ipsen deal

    Interprotein Corp., Osaka, Japan Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Business: Endocrine/Metabolic Ipsen and Interprotein partnered to develop therapeutic peptides to treat endocrine …

    Published on 11/23/2015
  • Jennerex Biotherapeutics, Transgene deal

    Jennerex Biotherapeutics Inc., San Francisco, Calif. Transgene S.A. (Euronext:TNG), Illkirch, France Business: Cancer SillaJen Inc. (Busan, South Korea), which acquired Jennerex in 2014, and Transgene amended a 2010 …

    Published on 11/23/2015
  • Ludwig Institute, CRI, Targovax deal

    Ludwig Institute for Cancer Research Ltd., New York, N.Y. Cancer Research Institute, New York, N.Y. Targovax A/S, Lysaker, Norway Business: Cancer The institutes partnered with Targovax to evaluate ONCOS-102 in …

    Published on 11/23/2015
  • Merck, GlaxoSmithKline deal

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Cancer The companies partnered to conduct a U.S. Phase I trial to evaluate Mercks Keytruda pembrolizumab with …

    Published on 11/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993